Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi SA (NYSE: SNY) unveils its next round of earnings Monday, July 29. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Sanofi's Earnings: A Preview

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)

The French drugmaker says a shipment of its vaccines will begin in mid-August, with all shipments expected to be completed by the end of November.

Sanofi expects one-month delay of vaccine shipments for fall flu season

What to Expect from Sanofi's (SNY) Q2 Earnings

AbbVie

Bayer AG

Merck

Roche Holding AG

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

Pfizer

SNY vs. PFE: Which Stock Is the Better Value Option?

SNY or PFE: Which Is the Better Value Stock Right Now?

The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.

FDA Accepts Sanofi's BLA for Myeloma Candidate to Review

Amgen

Gilead Sciences

Eli Lilly

Novo Nordisk

Teva Pharmaceutical

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Court Ruling Topples Trump Order, No Price Display in TV Ads

Johnson & Johnson

Rogers

Bristol-Myers

Novartis

Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

The Top 10 Biotechnology Companies (JNJ, ROG.VX)

GlaxoSmithKline

SPDR S&P Pharmaceuticals ETF

"We're working on it right now a favored nations clause where we pay the lower nation's price is, like Canada," President Donald Trump tells reporters.

Trump says administration preparing an executive order on drug prices

Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

Regeneron Pharmaceuticals

Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.

Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation

AstraZeneca

According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.

Stocks With Low Price-Sales Ratios

The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.

Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion

AnaptysBio stock tumbled Friday after the results of a study from Regeneron Pharmaceuticals and Sanofi cast doubt on the biotech company's ability to compete in asthma treatment.

Regeneron And Sanofi Tried To Outperform Themselves — And Couldn't

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

Sanofi on Wednesday said a reorganization of its research and development operation in Germany and France would result in 466 job cuts in the two countries.

Sanofi plans 466 job cuts as part of R&D reshuffle

Alphabet

Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.

Sanofi Partners Google to Build Healthcare Innovation Lab

Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.

Sanofi (SNY) in Focus: Stock Moves 5.5% Higher

With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth.

Sanofi's Leadership Transition: What You Need To Know

There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.

New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

In veteran drug salesman Paul Hudson, Sanofi's 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

France's Sanofi bets on new CEO to drive sluggish drug sales

French pharma giant Sanofi has appointed Paul Hudson as chief executive to replace Olivier Brandicourt, who will retire in September, the company said on Friday.

News for Sanofi Stock (SNY)